Therapeutic Response

Wild type KRAS and Wild type NRAS status confers therapeutic sensitivity to Fluorouracil in combination with Oxaliplatin and Panitumumab in patients with Colorectal Adenocarcinoma.

View API

Statements

Source and description

View API